These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25792492)

  • 1. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
    Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
    Osteoporos Int; 2015 Jun; 26(6):1857-64. PubMed ID: 25792492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG
    J Clin Oncol; 2008 Jun; 26(16):2644-52. PubMed ID: 18427147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.
    van Londen GJ; Perera S; Vujevich KT; Sereika SM; Bhattacharya R; Greenspan SL
    Bone; 2010 Mar; 46(3):655-9. PubMed ID: 19853678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
    Markopoulos C; Tzoracoleftherakis E; Polychronis A; Venizelos B; Dafni U; Xepapadakis G; Papadiamantis J; Zobolas V; Misitzis J; Kalogerakos K; Sarantopoulou A; Siasos N; Koukouras D; Antonopoulou Z; Lazarou S; Gogas H
    Breast Cancer Res; 2010; 12(2):R24. PubMed ID: 20398352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
    Sergi G; Pintore G; Falci C; Veronese N; Berton L; Perissinotto E; Basso U; Brunello A; Monfardini S; Manzato E; Coin A
    J Bone Miner Metab; 2012 Jul; 30(4):461-7. PubMed ID: 22160398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
    Waltman NL; Twiss JJ; Ott CD; Gross GJ; Lindsey AM; Moore TE; Berg K; Kupzyk K
    Osteoporos Int; 2010 Aug; 21(8):1361-9. PubMed ID: 19802506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Bhattacharya RK; Sereika SM; Brufsky A; Vogel VG
    J Clin Endocrinol Metab; 2007 Jan; 92(1):131-6. PubMed ID: 17047022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
    J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
    Prasad C; Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
    Bone; 2016 Sep; 90():123-6. PubMed ID: 27018037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
    Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
    Leung JY; Ho AY; Ip TP; Lee G; Kung AW
    Bone; 2005 Feb; 36(2):358-64. PubMed ID: 15780963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
    Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
    J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.